Undecimal Bio Exits Stealth With $18M Seed for siRNA Delivery

Undecimal Bio has launched with an $18 million seed round to advance small interfering RNA (siRNA) delivery beyond the liver, according to Pulse 2.0.

The figure anchors one of the more concrete debut stories in the nucleic acid drug delivery space this cycle. An $18 million seed is a serious check for a company whose entire premise rests on solving a single, well-defined technical problem: siRNA therapies work, but they mostly work in one organ.

What does the $18 million fund?

By Amara Osei

The money backs Undecimal Bio's effort to extend siRNA delivery to tissues outside the liver. Pulse 2.0, which first reported the launch, frames the round explicitly as capital to advance delivery "beyond the liver."

That framing matters. Current siRNA platforms — the class that produced approved liver-targeted therapies — rely heavily on mechanisms that naturally route conjugated molecules to hepatocytes. The liver gets the payload. Almost everything else does not. A delivery vehicle that reaches other tissues reliably would expand the addressable disease list from metabolic and liver disorders into far broader territory.

Undecimal Bio has not yet disclosed the round's investor list, per the Pulse 2.0 report. The company also has not detailed a pipeline, target tissues, or development timelines in the launch coverage.

Why is delivery beyond the liver the bottleneck?

siRNA drugs silence specific genes before proteins get made. The mechanism is proven, and regulators have cleared products in the class. The constraint isn't the biology of silencing — it's getting the molecule to the right cells intact.

Delivery chemistry, not target selection, has historically decided which siRNA programs survive. That's why a seed-stage company whose pitch is a delivery advance, rather than a single disease target, can command $18 million at inception. Investors aren't underwriting one indication. They're underwriting a platform that could carry many.

The liver bias isn't a minor limitation. It's the defining structural feature of the field's commercial history to date. Every credible attempt to break it — new conjugates, new lipid chemistries, tissue-targeted ligands — carries outsized value if it works, because the same vehicle can be re-pointed at sequential targets.

What happens next?

The near-term signals to watch from Undecimal Bio are standard for a seed-stage platform play: named investors, scientific founders and their publication record, the first disclosed target tissue, and any preclinical data timeline.

An $18 million seed buys roughly two to three years of runway for a small team in today's biotech cost environment, and that's the window in which the company will need to show its delivery chemistry distinguishes itself from the many failed or stalled attempts at extrahepatic siRNA targeting.

The round also reads as a temperature check on nucleic acid delivery funding. Capital for gene silencing platforms cooled after the 2020-2021 peak, and seed dollars now concentrate on teams with a specific answer to a specific barrier. Pulse 2.0's report positions Undecimal Bio squarely in that camp: one problem, one check, one shot at widening where siRNA can go.